Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Ltd (NY: BHVN )

50.88 +1.12 (+2.25%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd

< Previous 1 2 3 4 5 6 7 8 9 Next >
Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy
The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Acuity Brands, Nike And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Hewlett Packard Enterprise, Nvidia, Progress Software And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
Biohaven, a clinical-stage biopharmaceutical company, is attracting investors with promising results for its experimental drug. 
Via MarketBeat
BHVN Stock Earnings: Biohaven Misses EPS for Q2 2024
BHVN stock results show that Biohaven missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
BHVN Stock Earnings: Biohaven Misses EPS for Q1 2024
BHVN stock results show that Biohaven missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Dow Gains Over 50 Points; Elevai Labs Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Crude Oil Down Over 1%; US Manufacturing PMI Falls In September
Via Benzinga
Exposures Fossil Fuels
Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise
Biohaven announced topline results from its pivotal Study BHV4157-206-RWE, showing that troriluzole significantly slowed disease progression in spinocerebellar ataxia patients over three years. The... 
Via Benzinga
Exposures Product Safety
Biohaven, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga
Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease
The company is hoping to soon file for approval of what could be the first SCA treatment. 
Via Investor's Business Daily
This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Biohaven Stock Earns Relative Strength Rating Upgrade
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91. 
Via Investor's Business Daily
$1M Bet On Biohaven? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
The 3 Smartest Healthcare Stocks to Buy With $1K Right Now
The healthcare stocks to buy deserve more respect from investors who seek top-level growth outside of the tech sector. 
Via InvestorPlace
HP Posts Upbeat Earnings, Joins Foot Locker, American Superconductor, Red Robin Gourmet Burgers And Other Big Stocks Moving Higher On Thursday
Via Benzinga
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday. 
Via Investor's Business Daily
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
What's Going On With Biohaven Stock Wednesday?
The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two different studies and presented other updates. 
Via Benzinga
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
The company says it's still running additional testing of the drug, calling the results "positive." 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential. 
Via Benzinga
Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
These biotech stocks seem to be rich with intriguing growth plays going for very reasonable multiples this May. 
Via InvestorPlace
Around $1M Bet On Biohaven? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
3 Biotech Stocks to Buy on the Dip: April 2024
With medical innovation being a resilient space, investors can have confidence with these biotech stocks to buy on the dip. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.